Opus Point Partners Management as of Dec. 31, 2016
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 55 positions in its portfolio as reported in the December 2016 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
SPDR S&P Biotech (XBI) | 20.3 | $26M | 430k | 59.19 | |
Bristol Myers Squibb (BMY) | 6.3 | $7.9M | 135k | 58.44 | |
iShares NASDAQ Biotechnology Index (IBB) | 5.3 | $6.6M | 25k | 265.40 | |
Merck & Co (MRK) | 3.9 | $4.9M | 84k | 58.86 | |
Alkermes (ALKS) | 3.6 | $4.6M | 82k | 55.58 | |
Ionis Pharmaceuticals (IONS) | 3.0 | $3.7M | 78k | 47.83 | |
Pfizer (PFE) | 2.9 | $3.6M | 112k | 32.48 | |
Seattle Genetics | 2.9 | $3.6M | 68k | 52.77 | |
Incyte Corporation (INCY) | 2.8 | $3.5M | 35k | 100.28 | |
Proshares Tr pshs ult nasb (BIB) | 2.7 | $3.4M | 85k | 39.91 | |
Alnylam Pharmaceuticals (ALNY) | 2.6 | $3.3M | 89k | 37.44 | |
AstraZeneca (AZN) | 2.6 | $3.3M | 120k | 27.32 | |
Celgene Corporation | 2.5 | $3.2M | 27k | 115.74 | |
Qiagen | 2.5 | $3.1M | 112k | 28.02 | |
Biogen Idec (BIIB) | 2.5 | $3.1M | 11k | 283.57 | |
Alexion Pharmaceuticals | 2.4 | $3.1M | 25k | 122.33 | |
Mettler-Toledo International (MTD) | 2.4 | $3.0M | 7.2k | 418.61 | |
Regeneron Pharmaceuticals (REGN) | 2.2 | $2.8M | 7.7k | 367.13 | |
Amgen (AMGN) | 2.2 | $2.7M | 19k | 146.19 | |
BioMarin Pharmaceutical (BMRN) | 2.1 | $2.6M | 32k | 82.84 | |
Vertex Pharmaceuticals Incorporated (VRTX) | 2.0 | $2.5M | 33k | 73.66 | |
Illumina (ILMN) | 1.9 | $2.4M | 19k | 128.06 | |
Agios Pharmaceuticals (AGIO) | 1.9 | $2.3M | 56k | 41.73 | |
GlaxoSmithKline | 1.8 | $2.3M | 60k | 38.52 | |
Nektar Therapeutics (NKTR) | 1.8 | $2.3M | 184k | 12.27 | |
Pacira Pharmaceuticals (PCRX) | 1.3 | $1.6M | 50k | 32.30 | |
Tesaro | 1.1 | $1.3M | 10k | 134.50 | |
Clovis Oncology | 1.1 | $1.3M | 30k | 44.43 | |
Paratek Pharmaceuticals | 1.0 | $1.2M | 80k | 15.40 | |
Eli Lilly & Co. (LLY) | 0.9 | $1.1M | 15k | 73.53 | |
Adamas Pharmaceuticals | 0.8 | $1.0M | 60k | 16.90 | |
Medicines Company | 0.8 | $950k | 28k | 33.93 | |
New Senior Inv Grp | 0.7 | $819k | 84k | 9.78 | |
Ultragenyx Pharmaceutical (RARE) | 0.6 | $764k | 11k | 70.32 | |
Portola Pharmaceuticals | 0.5 | $561k | 25k | 22.44 | |
Contrafect | 0.4 | $525k | 300k | 1.75 | |
Direxion Shs Etf Tr sp biotch bl | 0.4 | $448k | 14k | 31.33 | |
Recro Pharma | 0.3 | $322k | 40k | 8.05 | |
ACADIA Pharmaceuticals (ACAD) | 0.2 | $290k | 10k | 28.88 | |
United Therapeutics Corporation (UTHR) | 0.2 | $280k | 2.0k | 143.52 | |
Lion Biotechnologies | 0.2 | $271k | 39k | 6.96 | |
Ligand Pharmaceuticals In (LGND) | 0.2 | $263k | 2.6k | 101.58 | |
Grifols S A Sponsored Adr R (GRFS) | 0.2 | $267k | 17k | 16.07 | |
Quintiles Transnatio Hldgs I | 0.2 | $260k | 3.4k | 76.07 | |
Charles River Laboratories (CRL) | 0.2 | $252k | 3.3k | 76.29 | |
Bio-techne Corporation (TECH) | 0.2 | $254k | 2.5k | 102.96 | |
Gilead Sciences (GILD) | 0.2 | $244k | 3.4k | 71.60 | |
Neurocrine Biosciences (NBIX) | 0.2 | $238k | 6.1k | 38.78 | |
Intrexon | 0.2 | $240k | 9.9k | 24.30 | |
Kite Pharma | 0.2 | $241k | 5.4k | 44.90 | |
Avexis | 0.2 | $239k | 5.0k | 47.80 | |
Myriad Genetics (MYGN) | 0.2 | $232k | 14k | 16.68 | |
Intercept Pharmaceuticals In | 0.2 | $232k | 2.1k | 108.67 | |
Juno Therapeutics | 0.2 | $216k | 12k | 18.82 | |
Seres Therapeutics (MCRB) | 0.1 | $139k | 14k | 9.93 |